Primary Hyperoxaluria Type 2 | News Search

跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

找到 98,994 条关于 “Primary Hyperoxaluria Type 2”

Oral Drug N-PPG Shows Complete Prevention of Kidney Stones and Death in Rare Disease Model

ABO-101 Gene Editing Therapy for Primary Hyperoxaluria Type 1 Granted Orphan Drug Designation by European Commission

Arbor Biotechnologies' ABO-101 Receives FDA Clearance for Phase 1/2 Trial in Primary Hyperoxaluria Type 1

YolTech's YOLT-203 Shows Promise in Primary Hyperoxaluria Type 1 with Positive Clinical Data

Primary Hyperoxaluria Pipeline Shows Promise with 6+ Therapies in Development as Gene Editing Advances

YolTech Therapeutics Receives FDA Clearance for First Pivotal Trial of In Vivo Gene-Editing Therapy for Primary Hyperoxaluria Type 1

Non-Viral CRISPR Therapy Shows Promise for Primary Hyperoxaluria Type 1 in Preclinical Study

FDA Clears IND for Arbor Biotechnologies' ABO-101 Gene-Editing Therapy for Primary Hyperoxaluria Type 1

First Patients Dosed in Phase 1 Trial of In Vivo CRISPR Therapy YOLT-203 for Primary Hyperoxaluria Type 1

HighTide Therapeutics' HTD1801 Achieves Primary Endpoint in Phase 3 Type 2 Diabetes Trial

第 1 页，共 2134 页